Trial intelligence / Profile preview

Short-term VrD versus long-term VRD in newly diagnosed multiple myeloma

ChiCTR1900027789Phase 4Not yet recruiting

Sponsor
First Affiliated Hospital, Zhejiang University School of Medicine
Start
Dec 2019
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
Countries
1
01

Overview

Phase 4, randomised, open-label trial of bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Complete remission rate and Overall response rate. Planned start Dec 2019; status: not yet recruiting.

02

Drugs

bortezomiblenalidomidedexamethasone
03

Conditions

multiple myeloma (MM)

Beyond the preview

Go deeper on ChiCTR1900027789.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR1900027789.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call